Abstract
I read with interest the recent study by Sever et al. ,1 which reported that patients originally assigned atorvastatin continued to demonstrate lower event rates in most cardiovascular endpoints after the termination of Lipid Lowering Arm of the ASCOT (ASCOT-LLA) trial, compared with those originally assigned placebo, although LDL-cholesterol levels were almost identical in the two groups during the 2 years extended follow-up period.1 These observations suggest sustained cardioprotective effects of atorvastatin after the cessation of active treatment in at-risk patients with …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.